Literature DB >> 32405182

Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.

Arka De1, Ajay Duseja1.   

Abstract

The histological spectrum of nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), NASH-related cirrhosis and hepatocellular carcinoma. Ballooning degeneration of hepatocytes with or without fibrosis is the key feature that differentiates NASH from NAFL. Liver biopsy is the only reliable method for diagnosing NAFL and differentiating it from NASH. Although the epidemiology of NAFLD is well described, the need for invasive biopsy limits our knowledge of the community prevalence of NAFL. Recent data suggest that the biochemical composition of hepatic steatosis may have a bearing on the disease. Triglycerides, the most commonly accumulated lipid, have a cytoprotective role because of their inert nature. Several paired liver biopsy studies and longitudinal follow-up studies have shown that NAFL is not completely benign as previously envisaged. NAFL can indeed progress to NASH and severe fibrosis, with progression being influenced by presence of baseline or worsening metabolic risk factors. Overall, NAFL carries a low risk of liver-related and overall mortality although the risk of cardiovascular mortality is similar to that of NASH. Current concepts suggest the presence of a dynamic bidirectional cycling between NAFL and NASH with slow progression of fibrosis in majority of the patients. The fact that ultimately it is the onset of progressive fibrosis that dictates clinical outcomes brings into question the relevance of distinguishing NAFL from NASH.
© 2019 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  NAFLD; NASH; Non-alcoholic fatty liver disease; fatty liver; hepatic steatosis

Year:  2019        PMID: 32405182      PMCID: PMC7212297          DOI: 10.1016/j.jceh.2019.09.005

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  49 in total

Review 1.  The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information.

Authors:  Ian A Rowe; Richard Parker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

2.  Prediction of nonalcoholic fatty liver in prospective liver donors.

Authors:  Narendra S Choudhary; Neeraj Saraf; Sanjiv Saigal; Ajay Duseja; Dheeraj Gautam; Lipika Lipi; Amit Rastogi; Sanjay Goja; Prashant Bhangui; Sumana K Ramchandra; Yalakanti Raghavendra Babu; Arvinder S Soin
Journal:  Clin Transplant       Date:  2017-02-13       Impact factor: 2.863

3.  Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians.

Authors:  Kaushal Madan; Yogesh Batra; S Datta Gupta; Bal Chander; K D Anand Rajan; M S Tewatia; S K Panda; S K Acharya
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

4.  Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity.

Authors:  Kavya Anjani; Marie Lhomme; Nataliya Sokolovska; Christine Poitou; Judith Aron-Wisnewsky; Jean-Luc Bouillot; Philippe Lesnik; Pierre Bedossa; Anatol Kontush; Karine Clement; Isabelle Dugail; Joan Tordjman
Journal:  J Hepatol       Date:  2014-11-08       Impact factor: 25.083

5.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Authors:  Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison
Journal:  Gastroenterology       Date:  2010-09-19       Impact factor: 22.682

6.  Nonalcoholic fatty liver is not associated with incident chronic kidney disease: a large histology-based comparison with healthy individuals.

Authors:  Narendra S Choudhary; Neeraj Saraf; Naveen Kumar; Rahul Rai; Sanjiv Saigal; Dheeraj Gautam; Lipika Lipi; Amit Rastogi; Sanjay Goja; Prashant Bhangui; Sumana K Ramchandra; Arvinder S Soin
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-04       Impact factor: 2.566

Review 7.  Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments.

Authors:  R Kwok; Y-K Tse; G L-H Wong; Y Ha; A U Lee; M C Ngu; H L-Y Chan; V W-S Wong
Journal:  Aliment Pharmacol Ther       Date:  2013-12-05       Impact factor: 8.171

8.  Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease.

Authors:  Ram V Nampoothiri; Ajay Duseja; Manish Rathi; Swastik Agrawal; Naresh Sachdeva; Manu Mehta; Harpal S Dhaliwal; Radha K Dhiman; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2017-12-30

9.  High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India.

Authors:  Ajay Duseja; Shaneez Najmy; Suchet Sachdev; Arnab Pal; Rati Ram Sharma; Neelam Marwah; Yogesh Chawla
Journal:  JGH Open       Date:  2019-01-16

10.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Julia Kozlitina; Eriks Smagris; Stefan Stender; Børge G Nordestgaard; Heather H Zhou; Anne Tybjærg-Hansen; Thomas F Vogt; Helen H Hobbs; Jonathan C Cohen
Journal:  Nat Genet       Date:  2014-02-16       Impact factor: 38.330

View more
  9 in total

1.  FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.

Authors:  Arka De; Amarjit Keisham; Saurabh Mishra; Manu Mehta; Nipun Verma; Madhumita Premkumar; Sunil Taneja; Ashim Das; Virendra Singh; Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2021-06-15

2.  Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition.

Authors:  Genta Kakiyama; Dalila Marques; Rebecca Martin; Hajime Takei; Daniel Rodriguez-Agudo; Sandra A LaSalle; Taishi Hashiguchi; Xiaoying Liu; Richard Green; Sandra Erickson; Gregorio Gil; Michael Fuchs; Mitsuyoshi Suzuki; Tsuyoshi Murai; Hiroshi Nittono; Phillip B Hylemon; Huiping Zhou; William M Pandak
Journal:  J Lipid Res       Date:  2020-10-02       Impact factor: 5.922

3.  Nonalcoholic Fatty Liver Disease: Lessons Learnt in the Last Five Years.

Authors:  Ajay Duseja; Radha K Dhiman; Madhumita Premkumar
Journal:  J Clin Exp Hepatol       Date:  2020-07-24

Review 4.  Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review.

Authors:  Natalia Rosso; Adam M Stephenson; Pablo J Giraudi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2021-04

5.  Pro-Resolving Lipid Mediator Resolvin E1 Mitigates the Progress of Diethylnitrosamine-Induced Liver Fibrosis in Sprague-Dawley Rats by Attenuating Fibrogenesis and Restricting Proliferation.

Authors:  Maria José Rodríguez; Francisca Herrera; Wendy Donoso; Iván Castillo; Roxana Orrego; Daniel R González; Jessica Zúñiga-Hernández
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

Review 6.  A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.

Authors:  Marinela Krizanac; Paola Berenice Mass Sanchez; Ralf Weiskirchen; Anastasia Asimakopoulos
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

Review 7.  Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity.

Authors:  Partha Pal; Rajan Palui; Sayantan Ray
Journal:  World J Hepatol       Date:  2021-11-27

8.  Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis.

Authors:  Sina Ghandian; Rahul Thapa; Anurag Garikipati; Gina Barnes; Abigail Green-Saxena; Jacob Calvert; Qingqing Mao; Ritankar Das
Journal:  JGH Open       Date:  2022-03-08

9.  Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care.

Authors:  Laurence J Dobbie; Mohamed Kassab; Andrew S Davison; Pete Grace; Daniel J Cuthbertson; Theresa J Hydes
Journal:  J Clin Med       Date:  2021-12-09       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.